Healthcare Equipment and Supplies
Company Overview of KineMed, Inc.
KineMed, Inc. develops and commercializes proprietary biomarker platform technology. The company focuses on applying its proprietary biomarker platform technology to drug development, prescription, and non-prescription medical diagnostics and the pairing of drugs with diagnostic biomarker tests. It plans to commercialize biomarkers in the areas of muscle biology, fibrotic diseases, neurodegenerative diseases, cardiometabolic diseases, skin care, and cancer. The company was founded in 2001 and is based in Emeryville, California.
5980 Horton Street
Emeryville, CA 94608
Founded in 2001
Key Executives for KineMed, Inc.
Co-Founder, Chairman and Chief Executive Officer
Co-Founder, Chairman of the Scientific Advisory Board, President, Chief Scientific Officer and Director
Chief Business Officer and Executive Vice President
Executive Vice President of Research & Development
Compensation as of Fiscal Year 2015.
KineMed, Inc. Key Developments
KineMed, Inc. and Pronutria Biosciences Enters Research and Development Collaboration
Jun 2 15
KineMed, Inc. and Pronutria Biosciences, Inc. announced a collaboration under which KineMed will apply its dynamic proteomics platform to assist Pronutria in evaluating novel biologics designed to restore cellular homeostasis in amino acid biology. Pronutria Biosciences is a clinical-stage biotechnology company pioneering a new class of therapeutics to mediate amino acid biology for patients facing serious diseases who currently have few or no treatment options. Pronutria is rapidly advancing research and development programs in several nutritional and therapeutic areas including myopenia (or muscle wasting), metabolic, neurological and liver disorders. Pronutria will utilize the KineMed platform to assess the physiologic effects of its compounds in preclinical and clinical studies. KineMed's ability to rapidly evaluate changes in protein balance is uniquely valuable in assessing the physiologic impact of proteins in different conditions, stated Robert Connelly, President and Chief Executive Officer of Pronutria. KineMed's dynamic proteomics platform is designed to rapidly detect target engagement, track disease progression and provide data that are predictive of later-stage clinical trial outcomes.
KineMed, Inc. Presents at JMP Securities Life Sciences Conference, Jun-24-2015 03:30 PM
May 23 15
KineMed, Inc. Presents at JMP Securities Life Sciences Conference, Jun-24-2015 03:30 PM. Venue: The St. Regis New York, 2 East 55th Street, New York, NY 10022, United States.
KineMed, Inc. Presents at BioEquity Europe 2015, May-19-2015 04:40 PM
May 8 15
KineMed, Inc. Presents at BioEquity Europe 2015, May-19-2015 04:40 PM. Venue: InterContinental Vienna, Vienna, Austria.
Similar Private Companies By Industry
Recent Private Companies Transactions
June 11, 2015